MapLight Therapeutics (MPLT) Net Cash Flow (2024 - 2025)
MapLight Therapeutics (MPLT) reported Net Cash Flow of -$17.4 million for Q4 2025, down 259.63% on a YoY basis from $10.9 million in Q4 2024, and down 259.63% sequentially from $10.9 million in Q4 2024.
MapLight Therapeutics (MPLT) Net Cash Flow (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Net Cash Flow data on file, last reported at -$17.4 million in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow fell 259.63% year-over-year to -$17.4 million; the trailing twelve-month figure through Dec 2025 stood at -$6.5 million (changed N/A YoY), and the FY2025 full-year result was $8.5 million, up 120.4% from the prior year.
- Net Cash Flow slipped to -$17.4 million in Q4 2025, from $10.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $10.9 million in Q4 2024 to a low of -$17.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | -17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Dec 31, 2024 | 10.91 Mn |